论文部分内容阅读
尽管使用多种药物组成的新方案治疗多发性骨髓瘤(MM),但在过去的20年中患者的平均存活期并无明显改善。有许多判断预后的标准,这些标准使人相信,治疗 MM 必须象治疗血液系统其他恶性肿瘤一样,要根据病情的严重程度选择治疗方案。在各种多药物组成的方案中 VMBCP 用得较广泛。最近使用 VAD 方案治疗对其他药物抗药的进展期 MM 取得良效,而且作用迅速。作者选择了一组Ⅲ期 MM 病人(这些病人还符合附加的表明病情严重的标准即Ⅲ SC),比较了用 VAD 或 VMBCP 治疗Ⅲ SC的结果。
Despite the use of multiple drug regimens for the treatment of multiple myeloma (MM), there has been no significant improvement in patients’ mean survival over the past 20 years. There are many criteria to judge the prognosis, these standards make people believe that the treatment of MM must be treated like other malignancies of the blood system, according to the severity of the disease to choose the treatment options. VMBCP is more widely used in various multi-drug regimens. The recent use of the VAD regimen for the treatment of advanced MM resistant to other drugs works well and has a rapid effect. The authors selected a group of patients with stage III MM (these patients also met the additional criteria that indicate a serious condition, SCI SC) and compared the results of SC with VAD or VMBCP.